Mark53 Studies
Led by Univ. Prof. Dr. Daniela Kandioler, between 1999 and 2013 the impact of the TP53 gene status on the response to chemotherapy or radiation therapy was investigated in clinical biomarker studies on more than 1,000 cancer patients at the Medical University of Vienna.
The study results, as well as ongoing biomarker studies with all study details, are to be found on the website of the research group p53research at: www.p53.at.
ABOUT 
With the Mark53 analysis, our company is making available a precise p53 gene test, which – for the first time – establishes the prerequisites for a broad clinical application of this biomarker. For the question, as to which patient responds to a cancer therapy and which does not, is a crucial one! We wish to pave the way for an efficient cancer therapy and continue to guarantee research that is independent of the pharmaceutical industry.